Renalytix plc
("Renalytix" or the
"Company")
Director/PDMR Dealing
LONDON and NEW YORK, 11 October 2024
- Renalytix plc (NASDAQ: RNLX)
(LSE: RENX), an artificial intelligence-enabled in vitro
diagnostics company, focused on optimizing clinical management of
kidney disease to drive improved patient outcomes and advance
value-based care, announces that on 7 October 2024,
certain investment vehicles connected with
Christopher Mills, Non-Executive Chairman, sold 83,696 ordinary
shares of £0.0025 each ("Ordinary Shares") in the Company at a
price of £0.08 per Ordinary Share.
Following this transaction, on 8
October 2024, certain investment vehicles connected with
Christopher Mills, completed the purchase of 500,000 ordinary shares of £0.0025
each ("Ordinary Shares") in the Company at a price of £0.09 per
Ordinary Share.
Following completion of both
transactions, Christopher Mills and the investment vehicles
connected with him are interested in 14,609,946 Ordinary Shares
representing 7.7% of the issued share capital of the Company as
enlarged by the recent equity placing announced on 30 September
2024.
For further information,
please contact:
|
Renalytix plc
|
www.renalytix.com
|
|
James McCullough, CEO
|
Via
Walbrook PR
|
|
|
|
|
Stifel (Nominated Adviser and Joint Broker)
|
Tel: 020
7710 7600
|
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
|
|
Oberon Capital
(Joint Broker)
|
Tel: 020
3179 5300
|
|
Mike Seabrook / Nick Lovering
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020
7933 8780 or renalytix@walbrookpr.com
|
|
Paul McManus / Alice Woodings
|
Mob: 07980 541 893 / 07407
804 654
|
|
|
|
|
CapComm Partners
|
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About
Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro
diagnostics and laboratory services company that is the global
founder and leader in the new field of bioprognosis™ for kidney
health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com.
Notification and public disclosure of
transactions by persons discharging managerial responsibilities and
persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Harwood Capital LLP*
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Christopher Mills, Non-Executive
Chairman, Chief Investment Officer of
Harwood
|
|
b)
|
Initial notification
/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Renalytix plc
|
|
b)
|
LEI
|
213800NTOH3FK3WER551
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares of £0.0025
each
|
|
|
|
|
Identification code
|
GB00BYWL4Y04
|
|
|
|
|
b)
|
Nature of the transaction
|
Sale of Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.08
|
83,696
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
83,696
|
|
|
|
|
- Price
|
£0.08
|
|
|
|
|
e)
|
Date of the transaction
|
7 October 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Harwood Capital LLP*
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Christopher Mills, Non-Executive
Chairman, Chief Investment Officer of
Harwood
|
|
b)
|
Initial notification
/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Renalytix plc
|
|
b)
|
LEI
|
213800NTOH3FK3WER551
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares of £0.0025
each
|
|
|
|
|
Identification code
|
GB00BYWL4Y04
|
|
|
|
|
b)
|
Nature of the transaction
|
Subscription for New Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.09
|
500,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
500,000
|
|
|
|
|
- Price
|
£0.09
|
|
|
|
|
e)
|
Date of the transaction
|
8 October 2024
|
|
f)
|
Place of the transaction
|
Off market
|
*Christopher Mills is partner and
Chief Investment Officer of Harwood Capital LLP. Harwood Capital
LLP is Investment Manager to North Atlantic Smaller Companies
Investment Trust plc and investment adviser to Oryx International
Growth Fund Limited. Christopher's shareholding is made up of
ordinary shares held by North Atlantic Smaller Companies Investment
Trust PLC, Oryx International Growth Fund Limited and Harwood
Capital LLP.